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Genetic perturbation of PU.1 binding and chromatin
looping at neutrophil enhancers associates
with autoimmune disease
Stephen Watt1, Louella Vasquez1,17, Klaudia Walter 1,17, Alice L. Mann1,17, Kousik Kundu 1,2, Lu Chen1,2,13,
Ying Sims1, Simone Ecker 3, Frances Burden4,5, Samantha Farrow4,5, Ben Farr1, Valentina Iotchkova 1,6,14,
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Neutrophils play fundamental roles in innate immune response, shape adaptive immunity,
and are a potentially causal cell type underpinning genetic associations with immune system
traits and diseases. Here, we proﬁle the binding of myeloid master regulator PU.1 in primary
neutrophils across nearly a hundred volunteers. We show that variants associated with
differential PU.1 binding underlie genetically-driven differences in cell count and susceptibility
to autoimmune and inﬂammatory diseases. We integrate these results with other multiindividual genomic readouts, revealing coordinated effects of PU.1 binding variants on the
local chromatin state, enhancer-promoter contacts and downstream gene expression, and
providing a functional interpretation for 27 genes underlying immune traits. Collectively,
these results demonstrate the functional role of PU.1 and its target enhancers in neutrophil
transcriptional control and immune disease susceptibility.
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eutrophils are the most abundant circulating leucocytes in
human blood, comprising up to 80% of the white blood
cell population. They form the body’s ﬁrst line of defence
against infection from pathogens1. As inﬂammatory cells, they
react to chemotactic signals and migrate to a wound or site of
infection to protect the organism from pathogenic insults. Neutrophils are phagocytes that envelope and consume microbial
invaders and on top of this capacity, they have an arsenal of
antimicrobial properties at their disposal. They are highly cytotoxic cells full of degradative enzymes including proteases,
hydrolases and nucleases2. In addition, neutrophils have the
ability to produce and release reactive oxygen species, which can
cross bacterial membranes damaging nucleic acids and proteins3.
One of the most striking capabilities of these cells is to use their
own DNA as a form of antimicrobial net in a process known as
NETosis4. This is a programmed form of cell death where the
neutrophil can release its chromatin to ensnare and kill larger
microbes that are difﬁcult to phagocytose such as fungal pathogens. As a collateral effect of their immune function, neutrophils
secrete highly cytotoxic molecules that can irritate or damage
surrounding tissues, contributing to inﬂammatory and autoimmune diseases5. However, it remains unknown to what extent
aberrations in neutrophil function can drive immune disorders6,7.
Pinpointing the causal cell types in these disorders is further
complicated by the known crosstalk between neutrophils and
other immune cell types such as B and T lymphocytes through
cytokine messaging and direct interactions8.
Genome-wide association studies (GWAS) are powerful tools
for identifying the genetic determinants of complex traits and
diseases, including autoimmunity. However, GWAS are cell typeagnostic and typically implicate non-coding variants that require
further interpretation to be actionable. Causal GWAS variants
preferentially localise to DNA regulatory elements such as
enhancers, which bind transcription factors (TFs) to activate and
ﬁne-tune target gene expression9,10. Enhancers are often located
large distances (up to megabases) away from their target genes
and typically exert their effects via direct DNA looping contacts
with their target gene promoters. Therefore, integrating GWAS
results with the readouts of genome conformation and epigenome
function is instrumental for identifying the causal cell types and
molecular mechanisms behind GWAS signals. For example,
enhancer activity is associated with speciﬁc patterns of chromatin
accessibility and histone modiﬁcations (such as histone H3 lysine
4 methylation and lysine 27 acetylation), and we and others have
previously shown that GWAS variants can associate with allelespeciﬁc imbalances in the magnitude of these readouts that
potentially mediate the variants’ expression effects11–14. The
allelic effects of non-coding GWAS variants on gene expression15,
as well as their three-dimensional (3D) contacts with gene promoters determined using high-resolution chromosomal architecture proﬁling, enable the identiﬁcation of target genes at
GWAS traits16,17.
PU.1 (encoded by SPI1 gene) is a master TF controlling
myeloid development18. PU.1 deﬁciency has profound effects on
neutrophil maturation and function19. PU.1 is known to bind
multitudes of enhancer elements in myeloid cells20. As a pioneer
TF, PU.1 is able to bind these regions in a repressive chromatin
state and activate them via the recruitment of other factors21,
including core chromatin activators and TFs such as C/EBPβ,
which is expressed throughout neutrophil development22. PU.1 is
required for modulating the response of mouse neutrophils to
infection23, but the emerging evidence for a role of this factor in
complex diseases is currently limited to other cell types. For
example, a common genetic variant within the SPI1 gene was
found to be associated with Alzheimer’s disease, with microglial
cells proposed as the likely causal cell type24.
2

Here, to study the effects of PU.1 on immune function in
human primary neutrophils, we use natural genetic variation
across humans as a high-throughput “perturbation experiment”
to identify PU.1 binding events in neutrophils that are subject to
genetic control. We show that variants associated with PU.1
differential binding (PU.1 tfQTLs) are enriched for genetic
associations with cell count and susceptibility to multiple autoimmune and inﬂammatory diseases. Integrating this information
with other multi-individual genomic readouts, we show that the
effects of genetically determined variation in PU.1 binding are
likely propagated through the local chromatin state and 3D
enhancer-promoter contacts to control the expression of diseaserelevant genes. Jointly, these results provide evidence for a
functional role of PU.1 in neutrophils in immune disease aetiology and provide mechanistic insights into the effects of noncoding genetic variation associated with healthy and pathological
immune traits.
Results
A multi-individual atlas of PU.1 binding and associated
genomic readouts. We generated PU.1 chromatin immunoprecipitation sequencing (ChIP-seq) data from CD66b+CD16+
neutrophils isolated from fully genotyped individuals forming
part of the BLUEPRINT project cohort14,25, with data from a
total of 93 donors passing quality control. In addition, we produced multi-individual data for two histone modiﬁcations, the
active mark H3K4me3 and the Polycomb-associated inhibitory
mark H3K27me3 in neutrophils isolated from the same donor
cohort (n = 107 and n = 106, respectively). We also proﬁled the
binding of the key PU.1 partner TF C/EBPβ and of the architectural protein CTCF in neutrophils (n = 22 and n = 30,
respectively), as well as the binding of the same TFs in classical
monocytes (PU.1, n = 10; C/EBPβ, n = 9; CTCF, n = 4) (Fig. 1a,
Supplementary Fig. 1a, b and Supplementary Data 1). We identiﬁed bound regions (peaks) in ChIP-seq data using established
algorithms (see “Methods”) and conﬁrmed data quality by
assessing the fraction of reads in peaks (FRiP), as well as using
principal component analysis and other approaches (Supplementary Fig. 1c–e and Supplementary Fig. 2a, b). Finally, we
obtained high-resolution chromosomal interaction proﬁles of
gene promoters in six individuals in neutrophils and monocytes
by combining newly generated and published16 Promoter Capture Hi-C (PCHi-C) datasets (Fig. 1a, Supplementary Fig. 3a–c).
Genetic determinants of PU.1 binding in neutrophils. To study
genetically determined variation in PU.1 binding to DNA, we
identiﬁed 36,530 high-conﬁdence PU.1 peaks across the 93
individuals (Methods) and used normalised read counts at peak
regions to determine TF quantitative trait loci associated with
PU.1 binding (PU.1 tfQTLs; “Methods”). We detected 1868
independent PU.1 binding QTLs (linkage disequilibrium [LD]
r2 ≥ 0.8; global false discovery rate [gFDR] <0.05; Supplementary
Fig. 2c–e and Supplementary Data 2).
Lead PU.1 tfQTL SNPs showed a bimodal distribution of
distances to their respective differential binding peaks (Fig. 1b,
Supplementary Data 3), with just over half of them (55%, 1,036/
1,868) mapping proximally from the peak edge (<2.5 kb; median
distance 264 bp), and the remaining SNPs (45%; 995/1,868)
localising more distally (2.5 kb-1 Mb, median distance 23 kb).
tfQTL effect sizes were stronger for proximal compared to distal
variants (Welch two-sided t-test p = 2.2 × 10−16, Fig. 1c) as
previously observed in cultured lymphoblastoid cells11,12. We
further validated a subset of the detected tfQTLs using allelespeciﬁc association analysis26 (“Methods”), which conﬁrmed a
signiﬁcant allelic imbalance for the majority of the tested peaks
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Fig. 1 Properties PU.1 transcription factor QTLs. a Summary of molecular traits generated as part of this study. b Density plot displaying the distance
between sentinel SNPs and their associated PU.1 peaks. The bimodal distribution (grey) can be further subdivided into proximal (solid navy, <2.5 kb) and
distal SNP effects (dotted, >2.5 kb). c Boxplot of absolute PU.1 tfQTL effect sizes (beta). Proximal PU.1 tfQTLs exhibit larger effect sizes compared to distal
tfQTLs (Welch two-sided t-test). Box plots show the medians (centre lines) and the 25th and 75th percentiles (box edges), with whiskers extending to 1.5
times the interquartile range. n = the number of PU.1 tfQTL in each category. d Proportion of signiﬁcant tfQTL SNPs with signiﬁcant allele-speciﬁc (A/S)
binding. Peaks without suitable heterozygous SNPs were not tested (grey).

(98.8% and 95.5% for peaks associated with proximal and distal
variants respectively; Fig. 1d).
PU.1 tfQTLs associate with differential binding of other TFs in
a distance-dependent manner. PU.1 binding to DNA leads to
extensive chromatin remodelling27 and redistribution of partner
co-factors28. C/EBPβ is upregulated throughout neutrophil
terminal differentiation22 and has been shown to co-occupy
myeloid enhancers at thousands of PU.1 bound sites20. In
contrast, the constitutively expressed CTCF is known to play a
role in gene regulation by anchoring chromatin interactions29,
but is not known to functionally associate with PU.1.
We identiﬁed 18,862 C/EBPβ and 22,197 CTCF ﬁltered peaks
from the datasets combined across individuals. We performed
tfQTL analysis as before, identifying 427 C/EBPβ and 769 CTCF
putative tfQTLs that reached a nominal p value threshold (p ≤ 1 ×
10−5; Supplementary Data 2). To assess the shared genetic effects
on the binding of PU.1 and these two TFs in cis, we focused on
proximal PU.1 tfQTLs and assessed the effect size on the nearest
C/EBPβ and CTCF QTLs (p ≤ 1) with respect to the lead SNP.
PU.1 tfQTLs showed decreasing effects on C/EBPβ binding with
increasing distance (linear regression p = 2.2 × 10−16), while no
distance dependence on CTCF binding was observed (p = 0.113)
(Fig. 2a, b). Indeed, signiﬁcant C/EBPβ QTLs (p ≤ 1 × 10−5, n =
92) were located proximal to the lead PU.1 tfQTL SNP, whereas
shared signiﬁcant CTCF tfQTLs (p ≤ 1 × 10−5, n = 135) were
located distally (Fig. 2c). These results conﬁrm that PU.1 and C/
EBPβ bind collaboratively and suggest long-range genetic effects
on CTCF binding.
Distal PU.1 binding variants are predominantly cell type speciﬁc. We asked to what extent the identiﬁed PU.1 tfQTLs were

speciﬁc to neutrophils. To this end, we additionally generated
PU.1-binding maps in primary (CD14+CD16−) monocytes isolated from ten BLUEPRINT donors, ﬁve of whom were also part
of the cohort used to proﬁle PU.1 binding in neutrophils. The
absolute majority (93%) of the PU.1-binding peaks associated
with a tfQTL in neutrophils were also detected in monocytes
(Supplementary Fig. 4a). The low number of individuals precluded an independent PU.1 tfQTL analysis in monocytes.
Therefore, to assess coordination of genetic effects at PU.1binding sites across cell types, we assessed the binding signal at
shared PU.1 and C/EBPβ-binding sites in monocytes with individuals stratiﬁed by lead PU.1 tfQTL genotype. We found that
monocytes displayed genotype associated changes in the strength
of binding at proximal SNPs (linear regression p = 3 × 10−9) as
observed in neutrophils (p = 2 × 10−13), compatible with shared
genetic effects between the two cell types. However, the same was
not true for distal SNPs (neutrophils p = 4 × 10−7, monocytes
p = 0.793; Fig. 2d). This data suggest that proximal tfQTL variants in related cell types operate under a similar cis-regulatory
mechanism, whereas long-range allelic control decays with distance and distal QTLs exhibit increased cell type speciﬁcity30.
PU.1 tfQTLs associate with local chromatin state. Given that
PU.1 is a pioneer factor, we expect the allelic effects of its binding
to inﬂuence the local chromatin state. To verify this, we detected
histone modiﬁcation-associated QTLs (hQTLs) for the active
H3K4me3 and repressive H3K27me3 histone marks in neutrophils and overlapped these data with PU.1 tfQTLs, identifying
621 and 367 shared PU.1 tfQTL/hQTL variants for these two
marks, respectively (Supplementary Data 2). Variant effects on
PU.1 binding and H3K4me3 tended to be in the same direction,
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Fig. 2 Effect of PU.1 SNPs on second transcription factor binding. a Mean effect size (95% conﬁdence intervals) for association of proximal sentinel PU.1
SNPs with the nearest C/EBPβ (light blue) and CTCF (red) binding site. The effect size decreases with distance for C/EBPβ (linear model p < 2.2 × 10−16)
but not for CTCF (linear model p = 0.113). Beneath: bar chart of number of peaks included in each distance bin. b Genome browser shot of an illustrative
example of tfQTL, where SNP rs8057431 (dashed line) alters a PU.1 motif and is associated with a disruption in binding of both PU.1 and C/EBPβ. With
signal box plots created from all individuals segregated by genotype. Box plots show the medians (centre lines) and the 25th and 75th percentiles (box
edges), with whiskers extending to 1.5 times the interquartile range. p values were obtained by ﬁtting linear mixed models implemented in LIMIX. n = the
number of independent donors. c Density plot displaying distance of lead proximal PU.1 SNP to the nearest shared association (p < 10−5) C/EBPβ (light
blue) or CTCF (red). d Transcription factor binding intensity for PU.1 (y axis Log RPMs) at shared PU.1 and C/EBPβ tfQTL from ﬁve matched individuals in
two cell types Neutrophils (left panel) and Monocytes (right panel). Binding sites were segregated by donor genotype (x-axis). tfQTL are categorised as
either proximal or distal (33 distal and 43 proximal) and linear models were ﬁtted separately for proximal and distal sites.

and in the opposite direction for PU.1 and H3K27me3 (Fig. 3a),
consistent with the predominantly activating role of PU.1 at these
loci. However, a signiﬁcant minority (n = 131) of PU.1 tfQTLs
showed the same direction of effect on PU.1 binding and the
levels of the H3K27me3 repressive mark, suggesting a role for
PU.1 acting as a repressor23. We additionally took advantage of
the previously published hQTL data for the enhancer-associated
histone marks H3K4me1 and H3K27ac14. In total, 808 H3K4me1
and 946 H3K27ac lead hQTL SNPs overlapped (r2 ≥ 0.8) PU.1
tfQTLs. Using the pi1 statistic31, we found evidence of sharing
between PU.1 tfQTLs with hQTLs in both neutrophils and
monocytes (pi1(H3K27ac) = 0.73-0.76, and pi1(H3K4me1) =
0.76-0.80). Sharing between neutrophil PU.1 tfQTLs and hQTLs
detected in CD4 naive T cells was lower (pi1H3K27ac = 0.36-0.72,
and pi1H3K4me1 = 0.30-0.79; Supplementary Fig. 4b), compatible
with PU.1 being expressed at a lower level and having distinct
4

functions in lymphoid cells (Supplementary Fig. 4c)32. Notably,
H3K27ac peaks co-occupied by PU.1 and C/EBPβ displayed
greater hQTL effect sizes compared to peaks bound by PU.1 alone
(Welch two-sided t-test p = 7.28 × 10−7; Fig. 3b), suggesting
stronger genetic effects for enhancers at co-occupied sites in
neutrophils. When compared with monocytes, neutrophil-speciﬁc
PU.1 and C/EBPβ binding associated with neutrophil-speciﬁc
chromatin activity (Supplementary Figs. 5 and 6). Collectively,
these results show that genetically determined differences in PU.1
binding associate with differential chromatin states in a tissuespeciﬁc manner.
We next assessed the distance between the PU.1 and histone
mark peaks for each shared tfQTL-hQTL genetic association. As
previously observed in lymphoblastoid cell lines (LCLs)11, there
was a pronounced bimodal distribution of distances between
PU.1 binding peaks and the locations of H3K27ac and H3K4me3
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Fig. 3 Neutrophil PU.1 tfQTLs and their association with chromatin state. a Bar plot displaying the number of shared associations (r2 ≥ 0.8) between
tfQTL and histone QTL. Bar plot is split into two categories, those cases where the beta between phenotypes are positively correlated, i.e., an allele leads to
a gain (an increase in signal) in both phenotypes. Or negatively correlated, where an allele associates with a gain in one phenotype and a reduction in the
second phenotype. The Pearson correlation between the betas is shown beneath. b Boxplot of absolute beta for H3K27ac neutrophil QTL (no signiﬁcance
threshold) for proximal lead PU.1 SNPs, differentiating H3K27ac regions that are or are not marked by C/EBPβ and/or CTCF binding. Box plots show the
medians (centre lines) and the 25th and 75th percentiles (box edges), with whiskers extending to 1.5 times the interquartile range. n = the number of PU.1
tfQTL that intersect H3K27ac hQTL. p value displayed above is a Welch two-sided t-test. c Density distribution plot of log distance between lead PU.1
tfQTL SNPs and shared (r2 ≥ 0.8) histone QTL in neutrophils.

marks (Fig. 3c), with around a half of PU.1 peaks localising to less
than 1 kb away from the respective H3K27ac and H3K4me3
peaks, and others mapping 10–100 kb from them. Given that
H3K4me3 is associated with active promoters, this observation
highlights the potential long-range regulatory effects of PU.1
binding to distal DNA elements on promoter activity.
Allelic effects of PU.1 on enhancer-promoter contacts. To
further explore the long-range effects of PU.1 binding, we utilised
our high-resolution PCHi-C data in neutrophils and monocytes
from six donors in total. We detected ~295,000 Promoter Interacting Regions (PIRs) in total across neutrophils and monocytes
(CHiCAGO score > 5)33, ~110,000 of which were detectable in
both cell types. We next explored the extent to which genetic
variation affecting PU.1 binding associates with differential
promoter-enhancer contacts. We employed an allele-speciﬁc
strategy (“Methods”) to identify heterozygous sites within PIRs
that exhibited allelic imbalance at PCHi-C contacts (Supplementary Fig. 7a-b). We found an enrichment of tfQTLs within
the ~14,000 heterozygous SNPs within PIRs that displayed evidence of allelic bias in both neutrophils and monocytes (Fig. 4a).
Notably, the same was true for the hQTLs including the
Polycomb-associated inhibitory mark H3K27me3, consistent with
a role of Polycomb repressive complexes in shaping regulatory
chromatin architecture34 (Supplementary Fig. 7c–e).
Effects of PU.1 tfQTLs on distal gene expression. To assess the
effects of PU.1 tfQTLs on distal gene expression, we initially took
advantage of expression QTL (eQTL) data generated from the
same individuals14, detecting 609 shared PU.1 tfQTLs/eQTLs
([LD] r2 ≥ 0.8), with a median distance from tfQTL to transcription start site of 56.5 kb. Notably, for 128 of 905 eQTL genes
PU.1 binding was negatively correlated with gene expression,
reinforcing the role of PU.1 as a dual transcriptional activator and
repressor23. An interesting example of a repressive PU.1 tfQTL
was rs2149092, associated with RNASET2 gene expression, and

previously implicated in the pathogenesis of inﬂammatory bowel
disease (IBD)35 (Supplementary Fig. 8a–c).
Distal eQTL signals do not discriminate between direct and
indirect effects. Therefore, to investigate the direct role of PU.1 in
long-range gene control, we again turned to our PCHi-C data.
PIRs enriched in neutrophil speciﬁc PU.1-binding sites (presented in Supplementary Fig. 6a) and enhancer-associated
H3K4me1/H3K27ac marks were positively correlated with the
level of expression of the genes they contacted in neutrophils
(Fig. 4b), similarly as shown for other cell types36. In contrast,
CTCF binding at PIRs did not correlate with target gene
expression (Fig. 4b), as expected given the constitutive nature
of many CTCF-mediated chromosomal interactions. In addition,
we observed no association with monocyte-speciﬁc PU.1 binding,
promoter interactions and gene expression levels (Fig. 4b).
Finally, we compared the effects of distal PU.1 tfQTLs/eQTLs
(>25 kb from TSS) mapping within and outside PIRs. PU.1
tfQTLs mapping to PIRs showed signiﬁcantly larger effects on the
expression of the genes they contacted compared with distancematched SNPs that did not map to a PIR (two-sided Fisher’s exact
test p < 2 × 10−16; Fig. 4c), demonstrating that the physical
enhancer-promoter contacts mediate the transcriptional effects of
PU.1 binding.
An example of a PU.1 tfQTL SNP showing allelic imbalance
affecting promoter-enhancer connectivity and gene expression is rs519989, an eQTL of the LRRC8C gene (Fig. 4d–g).
LRRC8C encodes a volume-regulated anion channel subunit
upregulated during terminal differentiation of neutrophils37. This
and other loci (including Supplementary Fig. 8c) demonstrate
coordinated genetic inﬂuences on PU.1 binding, chromatin
activity and the formation of promoter interactions in the
regulation of neutrophil gene expression.
PU.1 differential binding underpins disease-associated variants. Genome-wide association studies have been used to identify regions of the genome associated with phenotypic traits and
disease. In addition, TF-binding maps and epigenetic proﬁling
has been shown to assist in pinpointing the causal variants within
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Fig. 4 tfQTLs perturb gene expression through altered chromatin state. a Enrichment of signiﬁcant tfQTLs (PU.1 and CTCF; Fisher’s exact test p < 1 × 10−5)
in PIRs of both neutrophils and monocytes. The bars represent the mean and the error bars the 95% conﬁdence interval. b Heat map showing enrichment of
transcription factor or histone modiﬁed regions intersecting PIRs, whereby PIRs were ranked into four bins based on the gene expression of the connected
baited genes in neutrophils. c Density plot of gene expression QTL Beta value for neutrophil PU.1 SNPs within PIRs (navy) versus distance-matched signiﬁcant
SNPs not in PIRs (grey) (two-sided Fisher’s exact test p < 2 × 10−16), and distribution of beta values for SNPs within <25 kb of transcription start site (purple).
The SNPs that are not in PIRs are also signiﬁcant PU.1 tfQTLs and eQTLs (linear model p < 1 × 10−5 cut off). d CHiCAGO scores for the PIR at tfQTL,
segregated by donor genotype for rs519989. n the number of individual donors. e Signal box plots with donors separated by genotype for rs519989 for ﬁve
molecular traits, f boxplots displaying RNA level for LRRC8C gene segregated by donor genotype for SNP rs519989. n = the number of individual donors. Box
plots show the medians (centre lines) and the 25th and 75th percentiles (box edges), with whiskers extending to 1.5 times the interquartile range. p values
were obtained by ﬁtting linear mixed models implemented in LIMIX. g Genome browser view of region around LRRC8C gene, QTL regions for each molecular
trait are highlighted. Dashed line depicts the location of rs519989.

these regions and implicated mechanisms associated with complex traits. To look for evidence of a functional relationship
between our identiﬁed transcription factor binding sites and the
shaping of myeloid traits, we utilised available summary statistics
for monocyte and neutrophil counts38. Using GARFIELD
(GWAS Analysis of Regulatory or Functional Information
Enrichment with LD correction)39, we observed enrichment of
variants associated with full blood count (FBC) measurements within PU.1, C/EBPβ and, interestingly, CTCF bound
regions of the neutrophil genome (Fig. 5a). This analysis is suggestive of a relationship between regulatory regions of the neutrophil genome and genetic variants associated with myeloid
traits. To further investigate whether the identiﬁed tfQTLs
potentially inﬂuence human health, we took advantage of the
diverse range of reported traits in 361,194 individuals from the
UK Biobank study. We obtained summary statistics from 24
GWAS for autoimmune, allergy and infection associated traits
generated from the UK Biobank resource (http://www.nealelab.is/
uk-biobank/). From these we observed inﬂation of p values for
PU.1 tfQTLs within GWAS for hay fever, asthma, rheumatoid
arthritis (RA) and ulcerative colitis (UC), but perhaps somewhat
6

surprisingly, not at those associated with infections such Clostridium difﬁcile (Supplementary Fig. 9).
To formally test the overlap of PU.1 tfQTLs and haematological traits and diseases we accessed summary statistics from the
aforementioned GWAS on FBC traits38 and published autoimmune diseases40–45. Applying colocalisation analysis46,47
revealed 26 proximal and 53 distal tfQTLs that shared a genetic
signal (posterior probability [PP] > 0.9) with at least one GWAS
locus (Fig. 5b, Supplementary Data 4). We detected an overlapping signal at 4 loci (rs3784789, rs13089544, rs9262174 and
rs13035725) between tfQTL, FBC and disease GWAS, 3 of which
could be attributed to a lead SNP proximal to a PU.1-binding site.
To determine the putative target genes underpinning PU.1mediated disease associations, we integrated PCHi-C and eQTL
data in neutrophils. Overall, 27 high-conﬁdence target genes interacting with eQTL loci colocalised with GWAS summary statistics
(Supplementary Data 5).
An example of a PU.1 tfQTL associated with myeloid traits is the
rs791357_C variant associated with decreased neutrophil and
monocyte cell counts. PCHi-C data show that this region is highly
connected to the CPEB4 gene in both neutrophils and monocytes
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Fig. 5 tfQTLs inﬂuence cellular phenotype and disease. a Circos plots displaying fold-enrichment of GWAS loci for neutrophil count and monocyte count
within neutrophil regions marked by TF binding, modiﬁed histones and PU.1 and C/EBPβ speciﬁc binding sites in monocytes. Radial grid lines for published
GWAS p values, asterisk denotes signiﬁcance of enrichment for annotation tested at each GWAS p value cut off. b Bar plot displaying the number of
GWAS loci that colocalise with PU.1 tfQTL for both full blood count phenotypes (left) and autoimmune disease (right). c Example of colocalised signal for
sentinel SNP rs791357 tfQTL with a shared association for both neutrophil and monocyte count traits. Manhattan plots showing −log10(P) value for shared
SNPs from published GWAS for neutrophil and monocyte counts obtained by ﬁtting linear models, and PU.1 tfQTL (navy) obtained from LIMIX. With
genome browser visualisation of locus for CTCF, C/EBPβ and PU.1 binding shown beneath. The top associated peak is highlighted by the shaded area. In
addition, PCHi-C data show that this region is highly connected to the enhancer region in both neutrophils (blue) and monocytes (green). d Boxplot for TF
and RNA signal segregated by donor genotype. PU.1 (navy), CEBPβ (light blue), CPEB4 gene expression neutrophil (navy) and CPEB4 gene expression
monocyte (olive green). Box plots show the medians (centre lines) and the twenty-ﬁfth and seventy-ﬁfth percentiles (box edges), with whiskers extending
to 1.5 times the interquartile range. p values were obtained by ﬁtting linear mixed models implemented in LIMIX. n = the number of individual donors.

(Fig. 5c-d). CPEB4 is a cytoplasmic polyadenylation protein which
binds to a recognition sequence in the poly-A tail of mRNAs to
regulate translation48. The SNP rs791357 is a proximal tfQTL for
PU.1 (p = 9.05 × 10−21) and C/EBPβ (p = 1.963 × 10−9), an hQTL
for H3K4me3 (p = 1.98 × 10−17) and H3K27ac (p = 1.41×10−33)
and an eQTL for CPEB4 (p = 1.16 × 10−30) in neutrophils. Similar
sharing of PU.1 and C/EBPβ binding sites was observed in
monocytes with hQTL (H3K27ac p = 8.14 × 10−26) and eQTL for
CPEB4 (p = 2.55 × 10−18).
The aforementioned RNASET2 gene (Supplementary Fig. 8)
has been posited previously as an IBD risk-associated gene in
CD4+ T cells35. Moreover, it was identiﬁed as a target of TL1A, a
mediator of inﬂammation in the gut. In our neutrophil QTL data
we identiﬁed rs2149092 as the nearest SNP to the PU.1
tfQTL (chr6:167371914-167373868), which is in LD(r² = 1) with
the lead reported GWAS SNP rs1819333. We conﬁrmed a
colocalisation between this PU.1 tfQTL and GWAS for IBD and
Crohn’s disease (CD) ([PP] = 1). In addition, this tfQTL has a
signiﬁcant association with H3K4me3 (p = 6.11 × 10−17) at the

promoter of the RNASET2 gene, with the expression of
this gene itself (p = 5.75 × 10−61) and with a CTCF binding
site (p = 8.82 × 10−6) in the gene body. Interestingly, there was an
association with H3K27me3 (p = 3.71 × 10−22) at the promoter
region and with expression of the RPS6KA2 gene (p = 1.72 ×
10−23), which interacts with the lead SNP. The RPS6KA2 gene
has been implicated as an IBD risk-associated gene in an
epigenome-wide association study examining differentially
methylated regions in IBD patients from whole blood49. Here
we identify a genetic link suggesting that PU.1 is playing a pivotal
role in the underlying pathogenicity of IBD at this locus.
We further observed several examples of PU.1-mediated
gene regulation that may point to neutrophils as being
the effector cell type in the pathogenesis of inﬂammatory disease.
The GWAS colocalised loci include ﬁve shared tfQTL/eQTL in
neutrophils without a signiﬁcant eQTL in monocytes (rs6658646,
rs3768421, rs77120970, rs16895831 and rs3817465). The latter is
an eQTL for the autoimmune associated gene ILRAP18 (p =
2.16 × 10−27 in neutrophils and p = 0.0457 in monocytes). In
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addition we identiﬁed loci colocalised with genes that have been
previously implicated in neutrophil biology. For example CXCR2
is involved in neutrophil migration and has been implicated in
inﬂammatory disease, through the regulation of neutrophil
extracellular trap formation in patients suffering from chronic
obstructive pulmonary disease50. We observed a colocalised
signal for PU.1 tfQTL, rs13035725 (p = 2.44 × 10−10) with IBD
and UC. The same SNP is also signiﬁcantly associated with a
CTCF tfQTL (p = 5.52 × 10−6) and expression of several genes in
neutrophils, including CXCR2 (p = 4.25 × 10−13), ARPC2 (p =
3.70 × 10−20), AAMP (p = 1.02 × 10−8) and CXCR1 (p = 1.23 ×
10−6), all of which were weakly or not signiﬁcant in monocytes.
The region also displays high connectivity in the neutrophil
PCHi-C data (CHiCAGO score > 5), but is depleted of signiﬁcant
interactions in monocytes (Supplementary Fig. 10a, b).
The PLCL1 locus is another interesting example. The region
harbours variants associated with susceptibility to several diseases
including CD51, systemic lupus erythematosus52 and allergy53.
PLCL1 encodes the phospholipase C epsilon or phospholipase C
like I (inactive) signalling protein that has been shown to be
involved in receptor turnover but also inhibiting integrin
activity54, suggesting a role in the regulation of cell trafﬁcking.
We detected a colocalised signal with our PU.1 tfQTL and GWAS
for CD, with our lead tfQTL rs9712275 (p = 2.11 × 10−18) being
in high LD (r2 > 0.9) with the reported GWAS variant rs6738825.
In this case, the tfQTL contacts the PLCL1 gene promoter in both
neutrophils and monocytes and we observed evidence of allelic
imbalance in both cell types (Supplementary Fig. 10c, d). The lead
SNP rs9712275 is an eQTL for the PLCL1 gene in both
neutrophils (p = 2.86 × 10−27) and monocytes (p = 9.14 × 10−36).
Finally, we used CATO (Contextual Analysis of TF
Occupancy)47 to identify collaborating factors that may be
involved in mediating these traits at shared PU.1 tfQTL/GWAS
loci. Colocalising SNPs were shown to affect binding recognition
motifs for several PU.1 binding partners, including C/EBP, AP-1,
ETS, CTF/NF-1, ATF/CREB and RUNX (Supplementary Fig. 11).
These results highlight the likely role of PU.1 and its partners in
mediating the functional effects of GWAS variants in neutrophils.
Jointly, these ﬁndings demonstrate how genetically determined
variation in PU.1 binding, and potentially other partners,
underpins disease traits via altered chromatin states at regulatory
regions and long-range chromosomal contacts.
Discussion
In this study, we have leveraged common genetic variation as
“nature’s perturbation screen” to study the functional implications of the binding of key myeloid TF PU.1 in human primary
neutrophils. We have identiﬁed thousands of DNA variants
associated with altered PU.1 binding (both in cis and in trans),
and show that they also associate with downstream transcriptional regulatory events, including local chromatin state, longrange enhancer-promoter contacts and gene expression. We
further show that PU.1-binding variants underpin multiple
GWAS variants for healthy and pathological immune traits,
including autoimmunity, implicating PU.1 and neutrophils in the
aetiology of these processes.
GWAS have been deployed successfully over the last 15 years
to identify thousands of genetic loci associated with complex
traits and disease. To facilitate the utility of this endeavour into
tangible improvements in human health there remains a necessity
to identify disease-relevant cell types, biological pathways and
target genes. The epigenetic proﬁling of cell types implicated in
disease aids in the mapping of disease causative genetic
variants10,55. Our study adds to the emerging array of analyses
using multi-individual readouts of the chromatin state and TF
8

binding to understand the function of GWAS variants13. Many of
these studies, including multi-individual PU.1-binding
proﬁling11,56, were performed in LCLs. However, using diseaserelevant primary cells provides appropriate cellular context and
obviates in vitro artefacts, which is particularly important for
neutrophils that are known to have pronounced differences in
gene expression patterns from the established cell culture
models57. Inclusion of a second primary myeloid cell type in our
analysis (monocytes) has enabled pinpointing cell-type-speciﬁc
effects of genetic variation, and revealing that they preferentially
affect distal PU.1 tfQTLs.
The fact that large numbers of GWAS variants tag distal
enhancers makes the identiﬁcation of the target genes underpinning GWAS associations a challenging task. Insights from
expression quantitative trait loci (eQTLs) and 3D chromosomal
contacts between enhancers and promoters are proving to be
instrumental for GWAS gene assignment16,58. Here we used
neutrophil eQTL data from the BLUEPRINT project14 and highresolution PCHi-C data in primary neutrophils to link PU.1
tfQTLs and the GWAS variants they underpin with their target
genes. PCHi-C data from six individual donors, which emcompasses the most detailed datasets to date, also enabled us to
identify the potential allelic effects of promoter interactions
associated with PU.1 differential binding. This analysis extends
existing multi-individual studies using conventional Hi-C to
high-resolution promoter interaction analysis59,60. Both our and
the previous published analyses, however, used relatively small
numbers of individuals for chromosomal architecture proﬁling,
and further robust associations will likely be detected by future
higher-powered studies.
PU.1 has long been known as the key regulator of myeloid
development61. However, the role of this factor in mature neutrophils has remained less well explored. A recent study by
Fischer et al. has shown that deletion of PU.1 in mouse mature
neutrophils affects the expression of a multitude of genes involved
in immune response and results in a hyperinﬂammatory phenotype following infection23. Our ﬁndings that human neutrophil
PU.1 tfQTLs overlap eQTLs and autoimmune GWAS traits
provide further evidence for the role of this TF in controlling the
transcriptional state of mature neutrophils and point to potential
clinical implications of its aberrant binding.
Our observation that PU.1 binding associates with both active
and repressive chromatin marks, as well as both directly and
inversely correlates with the effects of overlapping eQTLs, corroborates the evidence from Fischer et al. of the importance of
PU.1 as a transcriptional repressor in the inﬂammatory context.
Our results are also consistent with the established role of PU.1’s
upstream regulator RUNX3 in autoimmune diseases such as
psoriatic arthritis62. TFs commonly act cooperatively63, and as
expected, many PU.1 binding variants have shared effects on the
binding of its partner TF C/EBP. Cooperativity likely underpins
the initially puzzling ﬁndings from complementary studies of
other TFs, which showed that the majority of TF-binding variants
are located outside the conventional TF motif64. Notably, the
abundance of distal PU.1 binding variants, consistent with previous ﬁndings11, suggests that such cooperativity may extend over
considerable genomic distances, potentially through DNA
looping30. The shared genetic effects that we observe on the
binding of PU.1 and the key chromosomal architectural protein
CTCF, in many cases with respect to sites mapping distally to
each other, support this view.
Over the recent years, neutrophils have emerged as important
regulators of autoimmune response. For example, neutrophils are
the most abundant cell type found in the synovial ﬂuid between
joints of RA patients65. In IBD, neutrophils are known to damage
the mucosal epithelium and release monocyte chemoattractants,
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leading to an extended inﬂammatory episode in the gut66. Our
ﬁndings that GWAS variants for autoimmune disease susceptibility affect the molecular phenotypes in primary neutrophils
reinforce the role of this cell type in autoimmunity and suggest
that neutrophils may, at least in some cases, play a driver role in
the development of these conditions as opposed to merely being
“support players” in autoimmune response.
Beyond the context of the present study, we release a large
resource of molecular phenotypes associated with non-coding
variants in primary immune cells that we envisage to be useful for
the community to further decipher the mechanistic underpinnings
of immune gene control and variant-disease associations, potentially used in conjunction with the emerging data on in vitro
mutagenesis and CRISPR-targeted chromatin perturbation67.
Methods
Peripheral adult blood collection. Data generated in this study used donor
samples which were collected as part of the previously described study14. Blood was
obtained from donors who were members of the NIHR Cambridge BioResource
(http://www.cambridgebioresource.org.uk/) with informed consent (Ethical oversight by NRES Committee East of England, Hertfordshire, Study title: A Blueprint
of Blood Cells, REC 12/EE/0040) at the NHS Blood and Transplant, Cambridge.
Donors were on average 55 years old (range 20–75 years old), with 46% of donors
being male. A unit of whole blood (475 ml) was collected in 3.2% sodium citrate.
An aliquot of this sample was collected in EDTA for genomic DNA puriﬁcation. A
FBC for all donors was obtained from an EDTA blood sample, collected in parallel
with the whole blood unit, using a Sysmex Haematological analyser. The level of
C-reactive protein (CRP), an inﬂammatory marker, was also measured in the sera
of all individuals. All donors used for the collection had FBC and CRP parameters
within the normal healthy range. Blood was processed within 4 h of collection.
Isolation of cell subsets. Samples were as those as described14. To obtain pure
samples of ‘classical’ monocytes (CD14+CD16−) and neutrophils (CD66b+CD16+)
we implemented a multi-step puriﬁcation strategy. Whole blood was diluted 1:1 in a
buffer of Dulbecco’s phosphate buffered saline (PBS, Sigma) containing 13 mM
sodium citrate tribasic dehydrate (Sigma) and 0.2% human serum albumin (HSA,
PAA) and separated using an isotonic Percoll gradient of 1.078 g/ml (Fisher Scientiﬁc). Peripheral blood mononuclear cells were collected and washed twice with
buffer, diluted to 25 million cells/ml and separated into two layers, a monocyte
rich layer and a lymphocyte rich layer, using a Percoll gradient of 1.066 g/ml. Cells
from each layer were washed in PBS (13 mM sodium citrate and 0.2% HSA) and
subsets puriﬁed using an antibody/magnetic bead strategy. To purify monocytes,
CD16+ cells were depleted from the monocyte rich layer using CD16 microbeads
(Miltenyi) according to the manufacturer’s instructions. Cells were washed in
PBS (13 mM sodium citrate and 0.2% HSA) and CD14+ cells were positively
selected using CD14 microbeads (Miltenyi). To purify neutrophils, the dense layer
of cells from the 1.078 g/ml Percoll separation was lysed twice using an ammonium
chloride buffer to remove erythrocytes. The resulting cells (including neutrophils
and eosinophils) were washed and neutrophils positively selected using CD16
microbeads (Miltenyi) according to the manufacturer’s instructions. The purity of
each cell preparation was assessed by multicolour FACS using conjugated antibodies
for CD14 (MφP9, BD Biosciences) and CD16 (B73.1 / leu11c, BD Biosciences) for
monocytes, CD16 (VEP13, MACS, Miltenyi) and CD66b (BIRMA 17C, IBGRLNHS) for neutrophils. Purity was on average 95% for monocytes and 98% for
neutrophils.
ChIP-sequencing. Puriﬁed cells were ﬁxed with 1% formaldehyde (Sigma) at a
concentration of approximately 10 million cells/ml. Fixed cell preparations were
washed and stored re-suspended in PBS at 4 °C prior to lysis and sonication.
Sonication protocols were performed in a Diagenode PicoRuptor for 8 cycles of
30 s on, 30 s off in a 4 °C water cooler. Samples were checked for sonication
efﬁciency using the criteria of 150–500 bp, by Agilent DNA bioanalyzer. ChIP-seq
was carried out as previously described68 all liquid handling steps were performed
on an Agilent Bravo NGS. Protein A Dynabeads (Invitrogen) were coupled with
2.5 μg of antibody. Sonicated lysate (3–5 million cells) was then added to the bead/
antibody mix and incubated at 4 °C overnight. ChIP-DNA bound beads were
washed for ten repetitions in cold RIPA solution. Elution of DNA from beads at
65 °C for 5 h to reverse the cross linking process. Two microlitres RNase was added
to ChIP-DNA and incubated at 37 °C for 30 min, followed by 2 μl of Proteinase K
treatment at 55 °C for 1 h. 1:1.8 ratio of Ampure beads (Beckman Coulter, A63881)
were added to the DNA followed by two cold 70% ethanol washes. ChIP-DNA was
eluted in 50 μl elution buffer. Illumina sequencing libraries were prepared on a
Beckman Fx liquid handling system. End-repair, A-tailing and paired-end adaptor
ligation were performed using NEBnext reagents from New England Biolabs
(E6000S), with puriﬁcation using a 1:1 ratio of AMPure XP to sample between each
reaction. Ampliﬁcation of ChIP-DNA was performed using Kapa HiFi master mix
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(Kapa Biosystems KK2602), 18 cycles of PCR followed by a 0.7:1 Ampure XP
clean-up. Antibodies for H3K4me3 (C15410003, lot A5051-001D), H3K27me3
(C15410195, lot A1811-001D), CTCF (C15410210, lot A2359-0010) were obtained
from Diagenode, Liege, Belgium. Antibodies for PU.1 (sc-352x, lot B2415 and sc22805x, lot D0609) and C/EBPβ (sc-150x, lot G1814) were obtained from Santa
Cruz Biotechnology.
Data processing and peak calling. ChIP libraries were sequenced using Illumina
HiSeq 2000 and HiSeq 2500 at 50 bp single end reads. Sequenced reads were
aligned to reference genome (hg19) using BWA (bwa aln –q 15). Duplicate reads
were marked using Picard MarkDuplicates (v1.103). Reads with mapping quality
less than 15 (MAPQ 15) were removed (SAMtools v0.1.18). The fragment size L for
each aligned bam was estimated using PhantomPeakQualTools vr18, which uses
cross correlation of binned read counts between forward and reverse strands. To
identify highly enriched genomic regions, we used MACS269 (v2.0.10.20131216,
standard options) for peak calling with the estimated fragment size from PhantomPeakQualTools (--shiftsize = half fragment size), with narrow for PU.1, C/
EBPβ, CTCF, H3K4me3 and broad ﬂags set for H3K27me3. For background
control ChIP input was created from merging random selected samples. Reads
from 4 pools of 12 individuals for neutrophil input and 2 pools of 6 individuals for
monocytes (Supplementary Data 1). Signiﬁcant peaks were selected to be at 1%
FDR or less.
Data quality. We removed ChIP samples that had a relative strand correlation
(RSC) < 0.8 and normalised strand correlation (NSC) < 1.0570. We deﬁned highconﬁdence data from those ChIP with RSC > 0.8 and NSC > 1.05. Otherwise, we
used genome browser tracks to conﬁrm visually a good ChIP and include it in the
ﬁnal data set. Supplementary Fig. 1 and Supplementary Data 1 shows quality
control metrics and corresponding principal components, showing no batch effects
after PEER correction using K = 10 factors.
Normalised read count in the reference peak sets. Consensus peak sets were
constructed using dba.peakset function within DiffBind R (ver3.4.0) package.
http://bioconductor.org/packages/release/bioc/vignettes/DiffBind/inst/doc/
DiffBind.pdf71. For PU.1, H3K4me3 and H3K27me3, we set the minimum number
of samples for a peak to be included in consensus to 3, for C/EBPβ, CTCF and
monocyte samples minimum was set to 2. Sex chromosomes were not included in
the QTL analysis. The reference peak set was ﬁltered further for read counts as
described below. Next, we generated a quantiﬁcation signal of ChIP-seq for each
donor. Here we only considered read counts under the peaks, as the regions outside
peaks are more likely to be noise or background signal than true enrichment. For
each donor, we generated a vector of log2 reads per million (log2RPM) per peak in
the reference peak set by counting the number of overlapping reads under the
peaks (BEDOPS v2.4.14 bedmap-count) and normalised the counts with the total
number of reads in the library. We further ﬁltered the reference peak set to only
consider peaks with log2RPM > 0 in at least 50% of the donors in a given cell type,
corrected for ten PEER factors and applied quantile normalisation across donors.
For QTL calling with H3K27me3, two sets of summary statistics are provided on
two separate signal matrices. In the ﬁrst set H3K4me3 peak annotations were used
in conjunction with H3K27me3 signal to enrich for poised promoter QTLs. In the
second set broad called H3K27me3 peaks were divided into 2500 bp windows.
Identiﬁcation of PU.1 and C/EBPβ differential binding sites. We used DiffBind
version 1.12.0 with default EdgeR (3.8.3) option to identify peaks which were
differentially bound between neutrophils and monocytes. For each cell type we
used the six best quality samples and their peak sets for this analysis; PU.1: NS1509,
NS1510, NS1511, NS1514, NS1516, NS1522, NS1463, NS1464, NS1554, NS1551,
NS1437 and NS1490. C/EBPβ; NS1559, NS1565, NS1563, NS1558, NS1562,
NS1566, NS585, NS743, NS791, NS729, NS717, and NS793. Quality control plots
generated as part of this analysis include correlation between sample peak sets
(Supplementary Fig. 5a) and PCA between samples using normalised counts within
consensus peak set (Supplementary Fig. 5b). Differentially bound peaks were
considered to those peaks present in at least three individuals with a minimum
threefold difference (FDR < 0.05) in binding signal as cut off. The heat map
visualisation of differentially bound regions Deeptools 2(Galaxy Version
3.3.2.0.1)72.
TF enrichments. For determining enrichment of ChIP-seq regions of interest
within PIRs we used regioneR (1.0.3)73, which performs a statistical evaluation of
two sets of genomic regions by permutation testing. We set to 50 permutations the
randomisation of genomic regions to determine the null. Differentially expressed
genes and gene expression counts. Gene expression counts and list of differentially
expressed genes were available from Ecker et al25.
QTL mapping. Cis-acting QTL mapping was done using the LIMIX package74,
available from github (https://github.com/PMBio/limix). We considered genetic
variants mapping to within 1 Mb (on each side) of each tested feature (peak), and
tested their association using linear regression. Models were ﬁt on quantile-
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normalised PEER residuals, also including a random effect term accounting for
polygenic signal and sample relatedness (as in the variance component models
above we used the realised relatedness matrix to capture sample relatedness). From
the linear regression we obtained the effect size and p value for each tested association. To correct for multiple hypothesis testing, we performed a two-step
procedure75: ﬁrst, we corrected for multiple testing across variants for each
molecular outcome using Bonferroni correction and, second, we adjusted the
obtained p values for multiple testing across phenotypes within each layer using a
the Q value procedure31, considered QTLs at a signiﬁcance threshold of 5% FDR.
PCHi-C. Cells were isolated as described16. One donor was used for preparing each
PCHi-C library. In total, 12 PCHi-C libraries were prepared, six using monocytes
and six using neutrophils. Approximately 8 × 107 cells per library were resuspended in 30.625 ml of DMEM supplemented with 10% FBS, and 4.375 ml of
formaldehyde was added (16% stock solution; 2% ﬁnal concentration). The ﬁxation
reaction continued for 10 min at room temperature with mixing and was then
quenched by the addition of 5 ml of 1 M glycine (125 mM ﬁnal concentration).
Cells were incubated at room temperature for 5 min and then on ice for 15 min.
Cells were pelleted by centrifugation at 400 g for 10 min at 4 °C, and the supernatant was discarded. The pellet was washed brieﬂy in cold PBS, and samples were
centrifuged again to pellet the cells. The supernatant was removed, and the cell
pellets were ﬂash frozen in liquid nitrogen and stored at −80 °C. HiC library
generation was carried with in-nucleus ligation as described previously76. Chromatin was then de-crosslinked and puriﬁed by phenol:chloroform extraction. DNA
concentration was measured using QuantiT PicoGreen (Life Technologies), and 40
μg of DNA was sheared to an average size of 400 bp, using the manufacturer’s
instructions (Covaris). The sheared DNA was end repaired, adenine tailed and
double size-selected using AMPure XP beads to isolate DNA ranging from 250 to
550 bp. Ligation fragments marked by biotin were immobilised using MyOne
Streptavidin C1 DynaBeads (Invitrogen) and ligated to paired-end adaptors (Illumina). The immobilised HiC libraries were ampliﬁed using PE PCR 1.0 and PE
PCR 2.0 primers (Illumina) with 7 PCR ampliﬁcation cycles. Capture HiC of
promoters was carried out with SureSelect target enrichment, using the custom
designed biotinylated RNA bait library and custom paired end blockers according
to the manufacturer’s instructions (Agilent Technologies). Biotinylated 120mer
RNA baits were designed to the ends of HindIII restriction fragments overlapping
Ensembl annotated promoters of protein coding, non-coding, antisense, snRNA,
miRNA and snoRNA transcripts36. A target sequence was accepted if its GC
content ranged between 25 and 65%, the sequence contained no more than two
consecutive Ns and was within 330 bp of the HindIII restriction fragment terminus.
A total of 22,076 HindIII fragments were captured, containing a total of 31,253
annotated promoters for 18,202 protein coding and 10,929 nonprotein genes
according to Ensembl v75 (http://grch37.ensembl.org). After library enrichment, a
post capture PCR ampliﬁcation step was carried out using PE PCR 1.0 and PE PCR
2.0 primers with 4 PCR ampliﬁcation cycles. PCHi-C libraries were sequenced on
the Illumina HiSeq 2500 platform3 50-PE sequencing lanes per PCHi-C library.
Sequencing reads were processed and mapped with HiCUP (version 0.5.5) and
PCHi-C interactions were called using CHiCAGO (version 0.2.5) with default
parameters33.
Genotyping check of ChIP-Seq and PCHi-C data. Identity matching for each
sample and for each analysis was performed by extracting genotypes from PCHi-C
and ChIP-seq and comparing them to SNPs from the WGS data. The ﬁrst stage of
verifying the sample identity concordance between the ChIP-seq and WGS data
involved pre-processing the BAM ﬁles for one autosomal chromosome (chr1) to
remove PCR duplicates and reads with mapping quality score <10. The variants
were then called from the resulting BAM ﬁle using mpileup from the SAMtools
package77. The variants with QUAL < 20, DP < 5 and GQ < 5 were ﬁltered out.
Then, we compared genotypes of the ﬁltered variants with genotypes generated
from WGS and imputation. The genotypes generated were considered to be from
the same sample if the concordance rate was greater than 90%.
Allele-speciﬁc analysis of TF binding. For allele-speciﬁc analysis, we used the
phased WGS VCF that was also utilised for QTL mapping but here we removed
indels and only considered biallelic single nucleotide variants. We then mapped
deduplicated ChIP-seq reads on each allele of each SNVs using GATK ASEReadCounter with default parameters, base quality ≥2 and mapping quality ≥15. We
then ﬁltered for heterozygous SNVs only with ≥10 read counts per site and nonzero
counts in both alleles. We required two donors meeting these read counts criteria at
each site. To carry out association analysis, we used Rasqual26 with total read
counts per sample as an offset parameter. Note that Rasqual uses a model that
corrects for reference mapping bias and genotyping errors. To correct for nongenetic confounders, we applied PCA with and without permutation on normalised
read counts in log2RPM across all sites and picked the ﬁrst N components whose
explained variances are greater than those from permutation as covariates for
Rasqual. Finally, we only considered SNVs found within peaks to determine the
direct allele-speciﬁc effect on TF binding of PU.1 and CTCF in neutrophils.
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Allele-speciﬁc analysis of PCHi-C. The genotypes of PCHi-C donors were
obtained from Cambridge Bioresource phase 4 (Illumina core exome chip). We
phased the genotype using BEAGLE2 (v2.0.5)78 and imputed using Positional
Burrows–Wheeler Transform and Haplotype Reference Consortium (release 1.1) as
reference panel, via the Sanger imputation service. We then ﬁltered sites for ≥5%
minor allele frequency, HWE p value ≥ 1 × 10−6, ≤5% sample missingness and
INFO score ≥0.8. We removed indels and only considered biallelic single nucleotide variants. We used WASP79 to remove PCHi-C reads that are likely to be biased
towards the reference allele. We then mapped deduplicated PCHI-C reads on each
allele of each SNVs using GATK ASEReadCounter with default parameters, base
quality ≥2 and mapping quality ≥15. We then ﬁltered for heterozygous SNVs only
with ≥10 read counts per site and nonzero counts in both alleles. Finally, we only
considered heterozygous sites with allele bias of ≤40% or ≥60%, after removing
extreme bias of <1% or >100%.
Enrichment analysis of tfQTLs and hQTLs in PIRs. Each of these heterozygous
SNVs was annotated based on whether they were located in a PIR and whether they
were signiﬁcant tfQTLs (PU.1 and CTCF; p < 1 × 10−5) or signiﬁcant hQTLs
(H3K27me3, H3K4me3, H3K27ac; p < 1 × 10−5). Fisher’s exact tests were carried
out separately for each sample and for each cell type to test for enrichment of
tfQTLs and hQTLs that fall into PIRs. Finally, the mean and standard deviation
were calculated across all samples for each cell type. In another approach, all
samples were combined across both cell types. SNVs were removed if they were not
observed in at least two samples, or in one sample and in the two cell types, or if the
allelic ratio (REF reads/ALT reads) was not consistent across the samples or cell
types. Enrichment was tested for SNVs where at least N samples fell into a PIR and
at least N samples carried a signiﬁcant tfQTL or hQTL for increasing number of
samples N (N = 1, 2, 3, 4).
Enrichment of genome-wide association SNPs within ChIP-seq marked
regions. To test for signiﬁcant enrichment of trait associated SNPs within regions
of interest, we applied GWAS analysis of regulatory or functional information
enrichment with LD (GARFIELD)39. H3K27ac and H3K4me1 occupied regions in
neutrophils were obtained from14. Neutrophil annotations for PU.1, C/EBPβ,
H3K4me3 and H3K27me3 were generated as described above. With the exception
that H3K27me3, regions were not chunked into 2.5 kb bins. Monocyte annotations
are obtained from data shown in Supplementary Fig. 6a for PU.1 and C/EBPβ.
Colocalisation between diseases and molecular trait. To overlap our QTL
results to GWAS catalogue, we calculated the LD information based on our WGS
data using plink v1.980. For all the QTLs that either directly mapped to the GWAS
variants or in LD (r2 ≥ 0.8), we considered that the QTL variant overlapped with a
GWAS signal. For the cases where we further selected six autoimmune diseases, we
took forward the overlapping disease variants with p value ≤5 × 10−8 in six selected
studies are coeliac disease40, IBD41, including CD and UC, multiple sclerosis42,
Type 1 diabetes43, and RA44. The associations of IBD, CD and UC in the European
cohorts were used for this study. We also used Type 2 diabetes45 as a negative
control. We used a Bayesian colocalization method46,81 to elucidate whether the
observed overlap between disease and molecular trait may be due to a shared
genetic effect. The method calculates the PP, versus the null model of no association, for four alternative models: a model where a region or locus contains a
single variant associated with either the molecular trait or disease (models 1 and 2);
a model where a single causal variant affects association with both traits (model 3);
or a model where two distinct associations exist (model 4). The method derives the
PP of each variant in the locus being causal one under different models, and the PP
of a given locus is then the integral sum of the PPs of all variants within, with all
variants under equal prior probability to be causal. The prior for each model is
computed to be one that maximises the log-likelihood function46. We acknowledge
the limitations of the model: it assumes one causal variant in the locus; and in the
case of high LD between two causal variants the model has limited power to
distinguish model 4 from model 3. We also note that colocalisation does not imply
a causal relationship between molecular trait and diseases, but may be compatible
also with the same variant having independent (‘pleiotropic’) effects on molecular
traits and disease. We applied a colocalisation test for each of the 1003 diseasemolecular trait pairs, where the lead SNPs in both traits are in r2 ≥ 0.8. To avoid
overlapping 2 Mb-wide genetic loci due to features in close proximity (e.g., splicing
junctions, genes, histones peaks, CpGs in islands), we tested colocalisation per
locus, which means that the prior model parameters were estimated using one
locus instead of multiple loci and hence the priors may be overestimated.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Data generated in this study was deposited to the European Genome-phenome Archive
under the following accession IDs: transcription factor data: EGAD00001004571;
H3K4me3: EGAD00001002711; H3K27me3: EGAD00001002712; PCHi-C:
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[http://www.nealelab.is/uk-biobank] UKBB GWAS Imputed v3 - File Manifest Release
20180731. All additional data are available from authors upon request. Source data are
provided with this paper.
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